Log in

MorphoSys News Headlines (ETR:MOR)

€114.10
-1.50 (-1.30 %)
(As of 02/21/2020 02:23 AM ET)
Today's Range
€113.80
Now: €114.10
€117.10
50-Day Range
€112.50
MA: €119.52
€136.20
52-Week Range
€79.70
Now: €114.10
€146.30
Volume114,488 shs
Average Volume153,687 shs
Market Capitalization$3.61 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

MorphoSys (ETR MOR) News Headlines

Source:
DateHeadline
Berenberg Bank Analysts Give MorphoSys (ETR:MOR) a €150.00 Price TargetBerenberg Bank Analysts Give MorphoSys (ETR:MOR) a €150.00 Price Target
www.americanbankingnews.com - February 5 at 6:01 PM
MorphoSys (ETR:MOR) Given a €110.00 Price Target by Barclays AnalystsMorphoSys (ETR:MOR) Given a €110.00 Price Target by Barclays Analysts
www.americanbankingnews.com - February 3 at 6:27 AM
MorphoSys AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionMorphoSys AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
uk.finance.yahoo.com - January 31 at 7:34 PM
MorphoSys AG (ETR:MOR) Given Consensus Recommendation of "Hold" by BrokeragesMorphoSys AG (ETR:MOR) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 28 at 8:01 AM
Flow Cytometry Market | Top players – BD Biosciences, Beckman Coulter, Merck Millipore, Amnis Corporation, Morphosys AGFlow Cytometry Market | Top players – BD Biosciences, Beckman Coulter, Merck Millipore, Amnis Corporation, Morphosys AG
www.marketwatch.com - January 23 at 8:52 AM
Incyte makes $750M upfront payment for rights to German cancer drugIncyte makes $750M upfront payment for rights to German cancer drug
www.bizjournals.com - January 13 at 5:53 PM
MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign...MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign...
www.benzinga.com - January 13 at 3:06 AM
MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for TafasitamabMorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
finance.yahoo.com - January 13 at 3:06 AM
Is MorphoSys AG (MOR) A Good Stock To Buy?Is MorphoSys AG (MOR) A Good Stock To Buy?
finance.yahoo.com - December 22 at 7:41 PM
Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazineMorphosys CFO says tafasitamab drug sales potential above $1 billion: magazine
www.reuters.com - November 30 at 8:09 AM
Chief scientist quits at Germanys Morphosys ahead of product launchChief scientist quits at Germany's Morphosys ahead of product launch
www.reuters.com - November 21 at 7:12 AM
Chief scientist quits at Germany's Morphosys ahead of product launchChief scientist quits at Germany's Morphosys ahead of product launch
finance.yahoo.com - November 21 at 7:12 AM
MorphoSys (ETR:MOR) Shareholders Have Enjoyed An Impressive 116% Share Price GainMorphoSys (ETR:MOR) Shareholders Have Enjoyed An Impressive 116% Share Price Gain
finance.yahoo.com - November 14 at 3:58 AM
DGAP-News: Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSyss PartnerDGAP-News: Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSys's Partner
www.bloomberg.com - November 11 at 5:30 PM
MorphoSys AG: Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSyss PartnerMorphoSys AG: Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner
www.finanznachrichten.de - November 11 at 5:30 PM
Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSyss PartnerResults for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner
www.bloomberg.com - November 11 at 5:30 PM
MorphoSys AG: MorphoSys to Present Data on Tafasitamab at ASH 2019 MeetingMorphoSys AG: MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting
www.finanznachrichten.de - November 6 at 8:44 PM
Chinese Biopharma I-Mab Files For U.S. IPOChinese Biopharma I-Mab Files For U.S. IPO
seekingalpha.com - November 4 at 6:26 PM
DGAP-Adhoc: MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the CombiDGAP-Adhoc: MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combi
www.bloomberg.com - October 30 at 2:40 PM
DGAP-News: MorphoSys AG Reports Third Quarter 2019 Financial ResultsDGAP-News: MorphoSys AG Reports Third Quarter 2019 Financial Results
www.bloomberg.com - October 30 at 2:40 PM
MorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the CombinatMorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combinat
www.bloomberg.com - October 29 at 5:49 PM
MorphoSys AG: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide AloneMorphoSys AG: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone
finance.yahoo.com - October 29 at 5:49 PM
MorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide AloneMorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone
finance.yahoo.com - October 29 at 5:49 PM
Morphosys ends development of dermatitis treatment, shares fallMorphosys ends development of dermatitis treatment, shares fall
www.reuters.com - October 29 at 7:48 AM
DGAP-News: MorphoSyss Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for TreatmDGAP-News: MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatm
www.bloomberg.com - September 16 at 8:19 AM
MorphoSyss Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for TreatmenMorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatmen
www.bloomberg.com - September 16 at 8:19 AM
CORRECTED-BRIEF-Morphosys Confirms Higher 2019 Revenue GuidanceCORRECTED-BRIEF-Morphosys Confirms Higher 2019 Revenue Guidance
www.reuters.com - August 7 at 9:19 PM
MorphoSys AG (MOR) Q2 2019 Earnings Call TranscriptMorphoSys AG (MOR) Q2 2019 Earnings Call Transcript
finance.yahoo.com - August 7 at 9:19 PM
MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines AgenMorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agen
www.bloomberg.com - August 6 at 5:12 PM
MorphoSys AG: MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCLMorphoSys AG: MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL
www.finanznachrichten.de - August 6 at 5:12 PM
MorphoSys AG Reports Second Quarter 2019 Financial ResultsMorphoSys AG Reports Second Quarter 2019 Financial Results
www.bloomberg.com - August 6 at 5:12 PM
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-OncologyMorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology
www.baystreet.ca - July 8 at 4:44 PM
Morphosys increases 2019 guidance thanks to milestone paymentMorphosys increases 2019 guidance thanks to milestone payment
www.nasdaq.com - July 3 at 10:38 AM
MorphoSys AG: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive OfficerMorphoSys AG: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
www.finanznachrichten.de - June 24 at 6:31 PM
MorphoSys appoints Jean-Paul Kress as new CEOMorphoSys appoints Jean-Paul Kress as new CEO
seekingalpha.com - June 24 at 6:31 PM
MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019
www.benzinga.com - June 22 at 10:27 AM
MorphoSys AG: MorphoSyss Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic ArthritisMorphoSys AG: MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis
www.finanznachrichten.de - June 14 at 12:40 PM
MorphoSyss Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic ArthritisMorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis
www.marketwatch.com - June 14 at 12:40 PM
MorphoSys (MOR) Presents At Goldman Sachs 40th Annual Global Healthcare Conference - SlideshowMorphoSys (MOR) Presents At Goldman Sachs 40th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - June 14 at 12:40 PM
MorphoSys AG Reports Outcome of Annual General Meeting 2019MorphoSys AG Reports Outcome of Annual General Meeting 2019
www.finanznachrichten.de - May 22 at 5:21 PM
Morphosys lead drug successful in mid-stage DLBCL studyMorphosys' lead drug successful in mid-stage DLBCL study
seekingalpha.com - May 16 at 5:13 PM
MorphoSys AG Reports First Quarter 2019 ResultsMorphoSys AG Reports First Quarter 2019 Results
www.bloomberg.com - May 7 at 5:12 PM
MorphoSys earns $3M milestone from I-Mab on start of multiple myeloma studyMorphoSys earns $3M milestone from I-Mab on start of multiple myeloma study
seekingalpha.com - April 30 at 10:23 AM
MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple MyelomaMorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
www.baystreet.ca - April 29 at 4:53 PM
Galapagos and MorphoSys announce initiation of GECKO Phase 2Galapagos and MorphoSys announce initiation of GECKO Phase 2
www.lse.co.uk - April 23 at 4:44 PM
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patientsGalapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
www.globenewswire.com - April 23 at 4:44 PM
Janssen launches development of Tremfya for rare intestinal polyp disorderJanssen launches development of Tremfya for rare intestinal polyp disorder
seekingalpha.com - April 15 at 5:15 PM
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous PolyposisMorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis
www.marketwatch.com - April 15 at 5:15 PM
MorphoSys Nominates New Candidate for Supervisory BoardMorphoSys Nominates New Candidate for Supervisory Board
www.baystreet.ca - April 10 at 5:12 PM
MorphoSys AG: Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor RelationsMorphoSys AG: Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations
www.finanznachrichten.de - April 1 at 4:56 PM
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: What is a stock buyback?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel